Zacks Investment Research upgraded shares of IMRIS INC (IMRS) from NEUTRAL to OUTPERFORM on December 27, 2013, with a target price of $1.60.
IMRIS Inc. provides image guided therapy solutions that deliver information to clinicians during surgical or interventional procedures. These solutions feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. Its products include, IMRISneuro, an integrated MR imaging system, IMRIScardio suite comprising a wide-bore 1.5 Tesla MR scanner and a single-plane angiography system and IMRISNV suite featuring a wide-bore 3 Tesla MRscanner and a bi-plane angiography system. IMRIS's application-specific solutions assist clinicians in treating neurological and cardiovascular conditions. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets. IMRIS Inc. is headquartered in Winnipeg, Canada.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on IMRIS INC (IMRS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment